Abstract
BackgroundZoledronate is recommended by European guidelines for the treatment of osteoporosis particularly where first-line oral drugs are ineffective or contraindicated. EULAR's guidelines are complimented by UK organisations including the National...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
